Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ATM | Q13315 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 2/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8130179 | 0.99 | KMT2A (0.67) | KMT2AATMMEN1ACECTSS | |
| SCHEMBL29602242 | 0.99 | KMT2A (0.67) | KMT2AATMMEN1ACECTSS | |
| SCHEMBL8530799 | 0.92 | REN (0.62) | KMT2AATMMEN1ACEREN | |
| SCHEMBL29275096 | 0.89 | CTSS (0.60) | KMT2AATMMEN1ACECTSS | |
| SCHEMBL7418843 | 0.89 | KLK5 (0.62) | KMT2AATMMEN1CTSSCTSL | |
| SCHEMBL27738325 | 0.89 | KLK5 (0.62) | KMT2AATMMEN1CTSSCTSL | |
| SCHEMBL17269324 | 0.89 | CTSS (0.60) | KMT2AATMMEN1ACECTSS | |
| SCHEMBL8614308 | 0.89 | CTSS (0.60) | KMT2AATMMEN1ACECTSS | |
| SCHEMBL9887475 | 0.89 | KLK5 (0.62) | KMT2AATMMEN1CTSSCTSL | |
| SCHEMBL24155486 | 0.88 | ACE (0.59) | KMT2AATMMEN1ACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | OGFR, OPRM1, CYP4F3 | KMT2A 3582/4885ATM 4828/4885MEN1 1736/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | KMT2A 4273/4885ATM 3634/4885MEN1 4435/4885 |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OGFR | KMT2A 4197/4885ATM 4879/4885MEN1 1775/4885 |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OGFR, OPRM1, CYP4F3 | KMT2A 3582/4885ATM 4828/4885MEN1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.